Safety of cell immunotherapy for refractory malignant tumor using natural killer cell-like effector cells (CA-MED-NK001) selectively amplified from autologous mononuclear cells in peripheral blood
- Conditions
- all classes of malignant tumors, after treatment with (or not applicable for) standard therapies for cancers
- Registration Number
- JPRN-UMIN000015733
- Lead Sponsor
- Center for Advanced Medical Innovation, Kyushu University
- Brief Summary
This trial has been terminated due to the difficulties of the recruitment of condition-matched subjects after the entry of four patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Not provided
Patients to be excluded would satisfy any of the following conditions: (1) pulmonary fibrosis and/or interstitial pneumonia (2) patients who have a history of severe drug allergy (3) serum positive for HBs antigen, HCV, HTLV-1 and/or HIV antibody (4) active autoimmune disease (5) patients who are taking steroids and/or immunosuprresive agents (6) double or more cancers (7) uncontrolable infectious disease (8) Patients to be or wishing for pregnancy, or breast-feeding (9) T cell- or NK cell-originated leukemia and/or lymphoma (10) heavy cardiological disease (11) Patientss who are regarded as inadequate for study enrollment by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety (Adverse events and their frequency, timing, duration and incidence rate)
- Secondary Outcome Measures
Name Time Method Efficacy and immunological response